Agreements reached under this partnership
Business alliance- 1
Agreement on the basic terms of a U.S. sales partnership
- 2
Negotiations on the detailed terms toward signing an exclusive sales license agreement
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
There is no change to the earnings forecast for the fiscal year ending December 2026. Any impact will be disclosed promptly once determined.
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals |
| Alliance partner's business activities | A U.S. specialty pharmaceutical company with more than 10 years of experience developing and marketing topical analgesics. Through a nationwide distribution network that includes independent retail pharmacies, specialty pharmacies and healthcare institutions, it markets prescription and over-the-counter topical patches and semisolid formulations, including lidocaine- and NSAID-based products. |
| Alliance partner's location | Reno, Nevada, U.S. |
| Type of alliance | Business alliance |
| Details of the alliance | Agreement on the basic terms of a U.S. sales partnership, Negotiations on the detailed terms toward signing an exclusive sales license agreement |
| Contract Date | September 2026 (expected) |
| Impact on Business Performance | There is no change to the earnings forecast for the fiscal year ending December 2026. Any impact will be disclosed promptly once determined. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales are expected to exceed the assumptions made when the basic terms were agreed, and additional time is required to review the sales strategy, supply plan and contractual terms.